LONDON, Oct. 11,
2023 /CNW/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the
global medical technology company specialising in orthopaedics,
advanced wound management and sports medicine, is pleased to
announce the opening of the purpose-built Smith+Nephew Academy
Munich, a new centre for surgical innovation and training.
S+N Academy Munich, situated in Kustermann Park in the heart of
the city, will provide a central European hub for surgeons from
across Europe, the Middle East and Africa. Surgeons and other healthcare
specialists will learn the latest surgical techniques using the
most advanced technology available, and practice surgical
techniques using both hands-on and fully immersive digital
interactive experiences.
S+N Academy Munich is the latest addition to a global
network of nine Academies, across three continents. At its peak,
S+N Academy Munich is expected to train up to 5,000 global
healthcare providers at the site each year.
Additionally, S+N Academy Munich will also serve as a hub to
connect healthcare professionals with its global marketing and
research and development teams to test and validate new
technologies.
'Our investment in S+N Academy Munich is part of a global
commitment to drive innovation and learning in medical technology,
creating an environment where the best healthcare providers can
learn, collaborate, and innovate in order to meet the needs of
their patients,' said Cynthia
Walker, Global Senior Vice President for Medical Education,
Smith+Nephew.
The ageing population, particularly in industrialised countries,
has led to a growing demand for new technology and digital
solutions to both improve outcomes and meet the cost-efficiencies
demanded by value-oriented healthcare systems. Smith+Nephew is
committed to ongoing investment in research and development to
further our purpose of ensuring patients can live their Life
Unlimited. The new S+N Academy Munich is another major
investment in the training and education of healthcare
professionals.
'In 2023, we launched more than 20 new products in orthopaedics,
sports medicine and wound care. The evolution of new technologies
is allowing us to constantly realise, develop and implement what's
possible in healthcare, improving outcomes for patients and meeting
the demands of health systems worldwide,' said Kenneth Garcia, Senior Vice President &
General Manager for Orthopaedics International, Smith+Nephew.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology company focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people's
bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 19,000
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product portfolio,
and the invention and application of new technologies across our
three global business units of Orthopaedics, Sports Medicine &
ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE: SN, NYSE: SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram or
Facebook.
Forward-looking statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading profit margins, market trends
and our product pipeline are forward-looking statements. Phrases
such as "aim", "plan", "intend", "anticipate", "well-placed",
"believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or
implied by the statements. For Smith+Nephew, these factors include:
risks related to the impact of Covid, such as the depth and
longevity of its impact, government actions and other restrictive
measures taken in response, material delays and cancellations of
elective procedures, reduced procedure capacity at medical
facilities, restricted access for sales representatives to medical
facilities, or our ability to execute business continuity plans as
a result of Covid; economic and financial conditions in the markets
we serve, especially those affecting healthcare providers, payers
and customers (including, without limitation, as a result of
Covid); price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal and financial compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers (including, without limitation, as a result of Covid);
competition for qualified personnel; strategic actions, including
acquisitions and disposals, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments;
relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to
natural disasters, weather and climate change related events;
changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC's website at www. sec.gov, for
a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
™Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/smithnephew-opens-new-state-of-the-art-surgical-innovation-and-training-centre-in-the-heart-of-munich-301953064.html
SOURCE Smith & Nephew plc